GRIA4 and cancer: VIPR2 was selected for its functional role and the involvement of vasoactive intestinal peptide receptors in cancer [21], while GRIA4 was chosen because it has previously shown methylation alterations in CRC tissues as well in plasma and stool samples [3,4].